Display Settings:

Format

Send to:

Choose Destination
    Clin Immunol. 2009 Feb;130(2):111-22. Epub 2008 Oct 19.

    Induction of mucosal tolerance in SLE: a sniff or a sip away from ameliorating lupus?

    Source

    Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. hwu@rics.bwh.harvard.edu

    Abstract

    Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by aberrant immune responses against intracellularly derived self antigens. Treatment for SLE relies on the use of aggressive immunosuppressants and steroids that are nonspecific and can cause serious adverse effects. The observation that a systemic immune tolerance to self antigens or generation of regulatory T cells may follow mucosal (nasal or oral) exposure to self proteins or monoclonal antibody against CD3 respectively suggests that induction of mucosal tolerance offers the basis of a side effect-free therapy that could re-establish the ability to distinguish self from non-self and restore peripheral tolerance in individuals susceptible to developing autoimmune diseases. Here I review studies on mucosal tolerance in autoimmune diseases and discuss the therapeutic potential of inducing tolerance for the treatment of SLE.

    PMID:
    18938110
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2652653
    Free PMC Article

    Images from this publication.See all images (2) Free text

    Diagram 1
    Diagram 2

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk